TERMIS - Americas Toronto, Ontario, Canada July 10-13, 2022
August 2022
in “
Tissue Engineering Part A
”
Studysummary This study observed that using ex vivo gene therapy to modify skin cells in a pre-graft model improved dermal-epidermal junction adhesion strength and maintained collagen production over time, suggesting a potential treatment approach for recessive dystrophic epidermolysis bullosa skin wounds. Our plain-language summary of this paper — not a Tressless recommendation.
The document summarizes various studies in skin tissue engineering and wound healing. Key findings include the use of ex vivo gene therapy to treat Recessive Dystrophic Epidermolysis Bullosa by inserting the COL7A1 gene into skin cells, which shows promise in restoring skin adhesion. A 3D skin model with a vascular plexus and hair follicles was developed to study immune cell trafficking. Another study created a vascularized 3D skin model with human immune cells for better disease study. Serpinb3a was identified as a potential therapeutic for accelerating wound healing, especially in diabetic wounds. Macrophages were found to aid tissue repair by inducing fibroblast contraction. These studies represent significant advancements in treating skin conditions and improving wound healing.
